Biotech | March 16, 2026
ShunzymeX leverages a proprietary protease to streamline purification
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
